Physician-scientists in the Cancer Center at Children’s Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells. The researchers published their findings today in Science Translational Medicine. “If there is an ultimate ‘bad guy’ of neuroblastomacell surface...